Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The product spreads like silk, leaving the face looking rested and subtly luminous
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
(2025) T2DM: 46.5% discontinued by 1 year 64.1% discontinued by 2 years Without T2DM: 64.8% discontinued by 1 year 84.4% discontinued by 2 years Key Factors Linked to Discontinuation: Higher rates among patients without T2DM Age 65 years More likely to discontinue Higher weight loss during treatment Associated with lower discontinuation rates Moderate to severe GI side effects Higher likelihood of stopping treatment Higher income (T2DM only) Lower discontinuation rates Reinitiation of GLP-1: Source: Rodriguez PJ, Zhang V, Gratzl S, et al
Neither development changes the case for CJC-1295 or ipamorelin
Insulin resistance is a big problem for the majority of people with PCOS
It helps manage blood sugar levels as a dual GIP and GLP-1 agonist
